Effects of a combination of antiangiogenic and antilymphangiogenic therapies on a death receptor-5 mediated antitumor immunotherapy in mice.

e23001Background: In angiogenesis, VEGF-A and its receptor VEGFR-2, and in lymphangiogenesis, VEGF-C and VEGFR-3, play central roles. An anti-tumor immunotherapy using an agonistic antibody (Ab) to...